Diffuse intrinsic pontine glioma cells are vulnerable to low intensity electric fields delivered by intratumoral modulation therapy
Tóm tắt
Diffuse intrinsic pontine glioma (DIPG) is a high fatality pediatric brain cancer without effective treatment. The field of electrotherapeutics offers new potential for other forms of glioma but the efficacy of this strategy has not been reported for DIPG. This pilot study evaluated the susceptibility of patient-derived DIPG cells to low intensity electric fields delivered using a developing technology called intratumoral modulation therapy (IMT). DIPG cells from autopsy specimens were treated with a custom-designed, in vitro IMT system. Computer-generated electric field simulation was performed to quantify IMT amplitude and distribution using continuous, low intensity, intermediate frequency stimulation parameters. Treatment groups included sham, IMT, temozolomide (TMZ) chemotherapy and radiation therapy (RT). The impact of single and multi-modality therapy was compared using spectrophotometric and flow cytometry viability analyses. DIPG cells exhibited robust, consistent susceptibility to IMT fields that significantly reduced cell viability compared to untreated control levels. The ratio of viable:non-viable DIPG cells transformed from ~ 6:1 in sham-treated to ~ 1.5:1 in IMT-treated conditions. The impact of IMT was similar to that of dual modality TMZ–RT therapy and the addition of IMT to this treatment combination dramatically reduced DIPG cell viability to ~ 20% of control values. This proof-of-concept study provides a novel demonstration of marked DIPG cell susceptibility to low intensity electric fields delivered using IMT. The potent impact as a monotherapy and when integrated into multi-modality treatment platforms justifies further investigations into the potential of IMT as a critically needed biomedical innovation for DIPG.
Tài liệu tham khảo
Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, Zhang J, Gajjar A, Dyer MA, Mullighan CG, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Ellison DW, Zhang J, Baker SJ, St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251–253
Johung TB, Monje M (2017) Diffuse intrinsic pontine glioma: new pathophysiological insights and emerging therapeutic targets. Curr Neuropharmacol 15(1):88–97
Harward S, Harrison Farber S, Malinzak M, Becher O, Thompson EM (2018) T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity. Childs Nerv Syst 34(3):449–455
Cohen KJ, Jabado N, Grill J (2017) Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro oncology 19(8):1025–1034
Long W, Yi Y, Chen S, Cao Q, Zhao W, Liu Q (2017) Potential new therapies for pediatric diffuse intrinsic pontine glioma. Front Pharmacol 8:1–13
Gwak HS, Park HJ (2017) Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Crit Rev Oncol Hematol 120:111–119
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192–2202
Fonkem E, Wong ET (2012) NovoTTF-100A: a new treatment modality for recurrent glioblastoma. Expert Rev Neurother 12:895–899
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316
Xu H, Bihari F, Whitehead S, Wong E, Schmid S, Hebb MO (2016) In vitro validation of intratumoral modulation therapy for glioblastoma. Anticancer Res 36:71–80
Di Sebastiano AR, Deweyert A, Benoit S, Iredale E, Xu H, De Oliveira C, Wong E, Schmid S, Hebb MO (2018) Preclinical outcomes of intratumoral modulation therapy for glioblastoma. Sci Rep 8:7301
Lin GL, Monje M (2017) A protocol for rapid post-mortem cell culture of diffuse intrinsic pontine glioma (DIPG). J Vis Exp 121:e55360
Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, Ni J, Duveau DY, Morris PJ, Zhao JJ, Thomas CJ, Monje M (2017) Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature 549(7673):533–537
Qin EY, Cooper DD, Abbott KL, Lennon J, Nagaraja S, Mackay A, Jones C, Vogel H, Jackson PK, Monje M (2017) Neural precursor-derived pleiotrophin mediates subventricular zone invasion by glioma. Cell 170(5):845–859
Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, Stupp R (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:3728–3736
Buch K, Peters T, Nawroth T, Sänger M, Schmidberger H, Langguth P (2012) Determination of cell survival after irradiation via clonogenic assay versus multiple MTT assay—a comparative study. Radiat Oncol 7:1
Smyth LM, Rogers PAW, Crosbie JC, Donoghue JF (2018) Characterization of diffuse intrinsic pontine glioma radiosensitivity using synchrotron microbeam radiotherapy and conventional radiation therapy in vitro. Radiat Res 189:146–155
Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y (2004) Disruption of cancer cell replication by alternating electric fields. Cancer Res 64:3288–3295
Palti Y (1996) Stimulation of internal organs by means of external applied electrodes. J Appl Physiol 21:1619–1623
Storm FK, Morton DL, Kaiser LR, Harrison WH, Elliott RS, Weisenburger TH, Parker RG, Haskell CM (1982) Clinical radiofrequency hyperthermia: a review. Natl Cancer Inst Monogr 61:343–350
Wenger C, Salvador R, Basser PJ, Miranda PC (2015) The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study. Phys Med Biol 60:7339–7357
Wenger C, Salvador R, Basser PJ, Miranda PC (2016) Improving tumor treating fields treatment efficacy in patients with glioblastoma using personalized array layouts. Int J Radiat Oncol Biol Phys 95:1137–1143
Pawłowski P, Szutowicz I, Marszałek P, Fikus M (1993) Bioelectrorheological model of the cell 5. Electrodestruction of cellular membrane in alternating electric field. Biophys J 65:541–549
Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD (2015) Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS ONE 10:e0125269
Morgenstern PF, Zhou Z, Wembacher-Schröder E, Cina V, Tsiouris AJ, Souweidane MM (2018) Clinical tolerance of corticospinal tracts in convection-enhanced delivery to the brainstem. J Neurosurg 21:1–7
van Vuurden DG (2018) Convection-enhanced delivery: chemosurgery in diffuse intrinsic pontine glioma. Lancet Oncol 19(8):1001–1003
Habets JGV, Heijmans M, Kuijf ML, Janssen MLF, Temel Y, Kubben PL (2018) An update on adaptive deep brain stimulation in Parkinson’s disease. Mov Disord 33(12):1834–1843
Ramirez-Zamora A, Ostrem JL (2018) Globus pallidus interna or subthalamic nucleus deep brain stimulation for Parkinson disease: a review. JAMA Neurol 75(3):367–372
Nowacki A, Galati S, Ai-Schlaeppi J, Bassetti C, Kaelin A, Pollo C (2018) Pedunculopontine nucleus: an integrative view with implications on deep brain stimulation. Neurobiol Dis. https://doi.org/10.1016/j.nbd.2018.08.015
Udupa K, Chen R (2015) The mechanisms of action of deep brain stimulation and ideas for the future development. Prog Neurobiol 133:27–49
Wichmann T, DeLong M (2016) Deep brain stimulation for movement disorders of basal ganglia origin: restoring function or functionality? Neurotherapeutics 12:264–283
Herrington T, Cheng J, Eskandar E (2016) Mechanisms of deep brain stimulation. J Neurophysiol 115:19–38
Hottinger AF, Pacheco P, Stupp R (2016) Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro oncology 18:1338–1349